Sağlık Bilimlerinde İleri Araştırmalar Dergisi

GÖNDERBİLGİ
EnglishTürkçe

Araştırma Makalesi


DOI :10.26650/JARHS2025-1742670   IUP :10.26650/JARHS2025-1742670    Tam Metin (PDF)

The lncRNA ATB–miR-200b Axis: Drug-Specific Regulation by Doxorubicin and Paclitaxel in ER-Positive Breast Cancer

Fatma Hande Karpuzoğlu, Ezgi Nurdan Yenilmez Tunoğlu

Objective: This study aimed to examine the expression patterns of long non-coding RNA ATB and microRNA-200b (miR-200b) in MCF-7 human breast cancer cells after treatment with two commonly used chemotherapeutic agents: doxorubicin (DOX) and paclitaxel (PTX). The goal was to determine whether the ATB–miR-200b regu latory axis influences drug-specific responses.

Materials and Methods:  MCF-7 cells were treated with IC₅₀ concentrations of DOX and PTX for 48 h. Total RNA was extracted, and cDNA was synthesised for both lncRNA and miRNA fractions. The expression levels of ATB and miR-200b were measured using quantitative real-time PCR (RT-qPCR). GAPDH and U6 served as internal references. Relative quantification was carried out using the 2−ΔΔCt method.

Results: lncRNA ATB expression was significantly decreased in both treatment groups (p < 0.05). Interestingly, miR-200b expression was decreased in PTX-treated cells but moderately increased in DOX treated cells. These results indicate a different regulatory response of the ATB–miR-200b axis depending on the chemotherapeutic agent used.

Conclusion: Our findings show that ATB and miR-200b respond differently to DOX and PTX exposure in MCF-7 cells. The simulta neous decrease of ATB and miR-200b in response to PTX may indicate EMT-related resistance mechanisms, whereas the increase of miR-200b in DOX-treated cells may be linked to apoptotic activation. More research is needed to understand the role of this regulatory axis in chemotherapy response.

Anahtar Kelimeler: Breast cancer, MCF-7 cell line, lncRNA ATB, miR-200b, doxorubicin, paclitaxel, RT-qPCR
DOI :10.26650/JARHS2025-1742670   IUP :10.26650/JARHS2025-1742670    Tam Metin (PDF)

lncRNA ATB-miR200b Aksisi: ER-Pozitif Meme Kanserinde Doksorubisin ve Paklitaksel ile İlaç Spesifik Düzenlenmesi

Fatma Hande Karpuzoğlu, Ezgi Nurdan Yenilmez Tunoğlu

Amaç: Bu çalışma, sık kullanılan iki kemoterapötik ajan olan doksorubisin (DOX) ve paklitaksel (PTX) uygulaması sonrasında insan meme kanseri hücre hattı MCF-7’de uzun kodlamayan RNA ATB (lncRNA ATB) ve mikroRNA-200b (miR-200b) ekspresyon paternlerini incelemeyi amaçlamıştır. Çalışmanın bir diğer amacı, ATB–miR-200b düzenleyici aksının ilaç-spesifik yanıtları etkileyip etkilemediğini ortaya koymaktır.

Gereç ve Yöntemler: MCF-7 hücreleri, DOX ve PTX’in IC₅₀ konsantrasyonlarıyla 48 saat süreyle muamele edilmiştir. Toplam RNA izole edilmiş, lncRNA ve miRNA fraksiyonları için cDNA sentezi yapılmıştır. ATB ve miR-200b ekspresyon düzeyleri kantitatif gerçek zamanlı PCR (RT-qPCR) yöntemiyle ölçülmüştür. lncRNA için GAPDH, miRNA için ise U6 referans gen olarak kullanılmıştır. Rölatif kantifikasyon 2−ΔΔCt yöntemi ile hesaplanmıştır.

Bulgular: lncRNA ATB ekspresyonu her iki tedavi grubunda da anlamlı düzeyde azalmıştır (p < 0,05). İlginç şekilde, miR-200b PTX ile muamele edilen hücrelerde azalmış, DOX ile muamele edilen hücrelerde ise orta derecede artış göstermiştir. Bu sonuçlar, kullanılan kemoterapötik ajana bağlı olarak ATB–miR-200b aksının farklı düzenleyici yanıtlar verebileceğini göstermektedir.

Sonuç: Bulgularımız, ATB ve miR-200b’nin MCF-7 hücrelerinde DOX ve PTX uygulamasına farklı yanıtlar verdiğini ortaya koymak tadır. PTX’e yanıt olarak hem ATB hem de miR-200b ekspresyonunun azalması, EMT (epitelyal-mezenkimal geçiş) ile ilişkili direnç mekanizmalarını düşündürmektedir. DOX uygulamasında miR-200b düzeyinin artması ise apoptoz aktivasyonu ile ilişkili olabilir. Bu düzenleyici aksın kemoterapi yanıtındaki rolünü netleştirmek için ileri çalışmalara ihtiyaç vardır.

Anahtar Kelimeler: Meme kanseri, MCF-7 hücre hattı, lncRNA ATB, miR-200b, Doksorubisin, Paklitaksel, RT-qPCR

PDF Görünüm

Referanslar

  • Siegel R, Kratzer L, Giaquinto TB, Sung AN, Jemal HA. Cancer statistics. Cancer J Clin 2025;75(1):10–45. google scholar
  • Waks AG, Winer EP. Breast cancer treatment. JAMA 2019;321(3):288. google scholar
  • Wang J, Wu SG. Breast Cancer. An overview of current therapeutic strategies, challenge, and perspectives. Breast Cancer: Targets and Therapy 2023;15:721-30. google scholar
  • Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, et al. Estimating the benefits of therapy for early-stage breast cancer. the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer: Annals of Oncology 2019;30(10):1541-57. google scholar
  • Martín M, Carrasco E, Rodríguez-Lescure Á, Andrés R, Servitja S, Antón A, et al. Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry. Breast Cancer Research and Treatment 2023;201(2):151-9. google scholar
  • Hurvitz SA, McAndrew NP, Bardia A, Press MF, Pegram M, Crown JP, et al. A careful reassessment of anthracycline use in curable breast cancer. Npj Breast Cancer 2021; 7(1). 134. google scholar
  • Giffoni de Mello Morais Mata D, Rush MB, Smith-Uffen M, Younus J, Lohmann AE, Trudeau M, et al. The Omission of anthracycline chemotherapy in women with early HER2-negative breast cancer-a systematic review and meta-analysis. Current Oncol 2024;31(8):4486-506. google scholar
  • Cardoso F, O’Shaughnessy J, Liu Z, McArthur H, Schmid P, Cortes J, et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer. a randomized phase 3 trial. Nature Medicine 2025;31(2):442-8. google scholar
  • Zhou FH, Downton T, Freelander A, Hurwitz J, Caldon CE, Lim E. CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective. Frontiers in Cell and Developmental Biol 2023;11. google scholar
  • Blancas-Zugarazo SS, Langley E, Hidalgo-Miranda A. Exosomal lncRNAs as regulators of breast cancer chemoresistance and metastasis and their potential use as biomarkers. Frontiers in Oncol 2024;14. google scholar
  • Weaver BA. How taxol/paclitaxel kills cancer cells. Mol Biol Cell 2014;25(18):2677-81. google scholar
  • Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell 2016;29(4):452-63. google scholar
  • Ye P, Feng L, Shi S, Dong C. The mechanisms of lncRNA-mediated multidrug resistance and the clinical application prospects of lncRNAs in breast cancer. Cancers 2022;14(9):2101. google scholar
  • Shi SJ, Wang LJ, Yu B, Li YH, Jin Y, Bai XZ. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget 20215;6(13):11652-63. google scholar
  • Yuan J, Yang F, Wang F, Ma J, Guo Y, Tao Q, et al. A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 2014;25(5):666-81. google scholar
  • Alnefaie GO. A review of the complex interplay between chemoresistance and lncRNAs in lung cancer. J Translational Med 2024;22(1):1109. google scholar
  • Ying Z, Wenjing S, Jing B, Songbin F, Kexian D. Advances in long non-coding RNA regulating drug resistance of cancer. Gene 2023;887:147726. google scholar
  • He M, Zhou W, Li C, Guo M. MicroRNAs, DNA damage response, and cancer treatment. Int J Mol Sci 2016;17(12):2087. google scholar
  • Si Z, Zhong Y, Lao S, Wu Y, Zhong G, Zeng W. The role of miRNAs in the resistance of anthracyclines in breast cancer. A systematic review. Frontiers Oncol 2022;12. google scholar
  • Olejniczak M, Kotowska-Zimmer A, Krzyzosiak W. Stress-induced changes in miRNA biogenesis and functioning. Cellular Mol Life Sci 2018;75(2):177-91. google scholar
  • Chen Q, Shen H, Zhu X, Liu Y, Yang H, Chen H, et al. A nuclear lncRNA Linc00839 as a Myc target to promote breast cancer chemoresistance via PI3K/AKT signaling pathway. Cancer Sci 2020;111(9):3279-91. google scholar
  • Chen S, Tu Y, Yuan H, Shi Z, Guo Y, Gong W, Tu S. Regulatory functions of miR 200b 3p in tumor development (Review). Oncol Reports 2022;47(5):96. google scholar
  • Tian J, Liu S, Yu C, Wu L, Wang L. The role of non-coding RNAs in breast cancer drug resistance. Frontiers Oncol 2021:11. google scholar

Atıflar

Biçimlendirilmiş bir atıfı kopyalayıp yapıştırın veya seçtiğiniz biçimde dışa aktarmak için seçeneklerden birini kullanın


DIŞA AKTAR



APA

Karpuzoğlu, F.H., & Yenilmez Tunoğlu, E. (2019). The lncRNA ATB–miR-200b Axis: Drug-Specific Regulation by Doxorubicin and Paclitaxel in ER-Positive Breast Cancer. Sağlık Bilimlerinde İleri Araştırmalar Dergisi, 0(0), -. https://doi.org/10.26650/JARHS2025-1742670


AMA

Karpuzoğlu F H, Yenilmez Tunoğlu E. The lncRNA ATB–miR-200b Axis: Drug-Specific Regulation by Doxorubicin and Paclitaxel in ER-Positive Breast Cancer. Sağlık Bilimlerinde İleri Araştırmalar Dergisi. 2019;0(0):-. https://doi.org/10.26650/JARHS2025-1742670


ABNT

Karpuzoğlu, F.H.; Yenilmez Tunoğlu, E. The lncRNA ATB–miR-200b Axis: Drug-Specific Regulation by Doxorubicin and Paclitaxel in ER-Positive Breast Cancer. Sağlık Bilimlerinde İleri Araştırmalar Dergisi, [Publisher Location], v. 0, n. 0, p. -, 2019.


Chicago: Author-Date Style

Karpuzoğlu, Fatma Hande, and Ezgi Nurdan Yenilmez Tunoğlu. 2019. “The lncRNA ATB–miR-200b Axis: Drug-Specific Regulation by Doxorubicin and Paclitaxel in ER-Positive Breast Cancer.” Sağlık Bilimlerinde İleri Araştırmalar Dergisi 0, no. 0: -. https://doi.org/10.26650/JARHS2025-1742670


Chicago: Humanities Style

Karpuzoğlu, Fatma Hande, and Ezgi Nurdan Yenilmez Tunoğlu. “The lncRNA ATB–miR-200b Axis: Drug-Specific Regulation by Doxorubicin and Paclitaxel in ER-Positive Breast Cancer.” Sağlık Bilimlerinde İleri Araştırmalar Dergisi 0, no. 0 (Sep. 2025): -. https://doi.org/10.26650/JARHS2025-1742670


Harvard: Australian Style

Karpuzoğlu, FH & Yenilmez Tunoğlu, E 2019, 'The lncRNA ATB–miR-200b Axis: Drug-Specific Regulation by Doxorubicin and Paclitaxel in ER-Positive Breast Cancer', Sağlık Bilimlerinde İleri Araştırmalar Dergisi, vol. 0, no. 0, pp. -, viewed 25 Sep. 2025, https://doi.org/10.26650/JARHS2025-1742670


Harvard: Author-Date Style

Karpuzoğlu, F.H. and Yenilmez Tunoğlu, E. (2019) ‘The lncRNA ATB–miR-200b Axis: Drug-Specific Regulation by Doxorubicin and Paclitaxel in ER-Positive Breast Cancer’, Sağlık Bilimlerinde İleri Araştırmalar Dergisi, 0(0), pp. -. https://doi.org/10.26650/JARHS2025-1742670 (25 Sep. 2025).


MLA

Karpuzoğlu, Fatma Hande, and Ezgi Nurdan Yenilmez Tunoğlu. “The lncRNA ATB–miR-200b Axis: Drug-Specific Regulation by Doxorubicin and Paclitaxel in ER-Positive Breast Cancer.” Sağlık Bilimlerinde İleri Araştırmalar Dergisi, vol. 0, no. 0, 2019, pp. -. [Database Container], https://doi.org/10.26650/JARHS2025-1742670


Vancouver

Karpuzoğlu FH, Yenilmez Tunoğlu E. The lncRNA ATB–miR-200b Axis: Drug-Specific Regulation by Doxorubicin and Paclitaxel in ER-Positive Breast Cancer. Sağlık Bilimlerinde İleri Araştırmalar Dergisi [Internet]. 25 Sep. 2025 [cited 25 Sep. 2025];0(0):-. Available from: https://doi.org/10.26650/JARHS2025-1742670 doi: 10.26650/JARHS2025-1742670


ISNAD

Karpuzoğlu, FatmaHande - Yenilmez Tunoğlu, Ezgi Nurdan. “The lncRNA ATB–miR-200b Axis: Drug-Specific Regulation by Doxorubicin and Paclitaxel in ER-Positive Breast Cancer”. Sağlık Bilimlerinde İleri Araştırmalar Dergisi 0/0 (Sep. 2025): -. https://doi.org/10.26650/JARHS2025-1742670



ZAMAN ÇİZELGESİ


Gönderim16.07.2025
Kabul19.08.2025
Çevrimiçi Yayınlanma11.09.2025

LİSANS


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


PAYLAŞ



İstanbul Üniversitesi Yayınları, uluslararası yayıncılık standartları ve etiğine uygun olarak, yüksek kalitede bilimsel dergi ve kitapların yayınlanmasıyla giderek artan bilimsel bilginin yayılmasına katkıda bulunmayı amaçlamaktadır. İstanbul Üniversitesi Yayınları açık erişimli, ticari olmayan, bilimsel yayıncılığı takip etmektedir.